ICMH
IBER

Integrity Capital Management (HK)’s Ibere Pharmaceuticals IBER Stock Holding History

Integrity Capital Management (HK)’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-46,717
Closed -$458K – 82
2022
Q1 		$458K Hold
46,717
– – 2.36% 8
2021
Q4 		$454K Buy
+46,717
New +$454K 1.44% 12

Other funds holding IBER

Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Integrity Capital Management (HK)'s IBER Position: Q2 2022 in Review

Integrity Capital Management (HK) sold out of Ibere Pharmaceuticals (IBER) in Q2 2022, closing a stake of 46,717 shares — an estimated $458K sold.

Integrity Capital Management (HK) first reported a position in IBER in Q4 2021 and held it in 2 quarters. The position peaked at $458K in Q1 2022. 46 funds tracked by Wall St. Rank hold IBER as of Q2 2022.

  • Integrity Capital Management (HK) reported no remaining Ibere Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Integrity Capital Management (HK) sold 46,717 Ibere Pharmaceuticals shares in Q2 2022, an estimated $458K.
  • Integrity Capital Management (HK) first reported a position in Ibere Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Integrity Capital Management (HK)'s Ibere Pharmaceuticals position peaked at $458K in Q1 2022.
  • 46 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q2 2022.

Based on Integrity Capital Management (HK)'s 13F filing for Q2 2022, filed 28 Jul 2022.